Human Genome Epidemiology Literature Finder
|
Records 1 - 11 (of 11 Records) |
| Query Trace: Neoplasms and CES1[original query] |
|---|
| Irinotecan pathway genotype analysis to predict pharmacokinetics. Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Aug 9 (9): 3246-53. Mathijssen Ron H J, Marsh Sharon, Karlsson Mats O, Xie Rujia, Baker Sharyn D, Verweij Jaap, Sparreboom Alex, McLeod Howard |
| Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients. British journal of clinical pharmacology 2010 Aug 70 (2): 222-33. Sai Kimie, Saito Yoshiro, Tatewaki Naoko, Hosokawa Masakiyo, Kaniwa Nahoko, Nishimaki-Mogami Tomoko, Naito Mikihiko, Sawada Jun-Ichi, Shirao Kuniaki, Hamaguchi Tetsuya, Yamamoto Noboru, Kunitoh Hideo, Tamura Tomohide, Yamada Yasuhide, Ohe Yuichiro, Yoshida Teruhiko, Minami Hironobu, Ohtsu Atsushi, Matsumura Yasuhiro, Saijo Nagahiro, Okuda Haruhi |
| OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy. British journal of cancer 2015 Mar 112 (5): 857-65. Teft W A, Welch S, Lenehan J, Parfitt J, Choi Y-H, Winquist E, Kim R |
| Identification of new SNPs associated with severe toxicity to capecitabine. Pharmacological research 2017 Mar 120 133-137. Pellicer Marta, García-González Xandra, García María I, Robles Luis, Grávalos Cristina, García-Alfonso Pilar, Pachón Vanessa, Longo Federico, Martínez Virginia, Blanco Carolina, Iglesias Irene, Sanjurjo María, López-Fernández Luis |
| Genetic Analysis Reveals a Significant Contribution of CES1 to Prostate Cancer Progression in Taiwanese Men. Cancers 2020 May 12 (5): . Ke Chien-Chih, Chen Lih-Chyang, Yu Chia-Cheng, Cheng Wei-Chung, Huang Chao-Yuan, Lin Victor C, Lu Te-Ling, Huang Shu-Pin, Bao Bo-Yi |
| Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients. Cancer chemotherapy and pharmacology 2020 5 85 (6): 1119-1128. Matsumoto Natsumi, Kubota Yutaro, Ishida Hiroo, Sekido Masae, Ohkuma Ryotaro, Ishiguro Tomoyuki, Hirasawa Yuya, Ariizumi Hirotsugu, Tsunoda Takuya, Ikusue Toshikazu, Kobayashi Kouji, Hisamatsu Atsushi, Toshima Hirokazu, Shimada Ken, Fujita Ken-Ic |
| Carboxylesterase 1 polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine. Cancer chemotherapy and pharmacology 2021 Feb . Liu Duo, Li Xuehua, Li Xiang, Wang Huiqi, Dong M |
| Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1. Clinical pharmacokinetics 2023 9 . Mirjam de With, Leni van Doorn, Esmay Kloet, Anne van Veggel, Maja Matic, Micha J de Neijs, Esther Oomen-de Hoop, Esther van Meerten, Ron H N van Schaik, Ron H J Mathijssen, Sander Bi |
| Association of Single-Nucleotide Polymorphisms in Capecitabine Bioactivation Pathway with Adjuvant Therapy Safety in Colorectal Cancer Patients. Pharmaceutics 2023 11 15 (11): . Yasmin Cura, Almudena Sánchez-Martín, Noelia Márquez-Pete, Encarnación González-Flores, Fernando Martínez-Martínez, Cristina Pérez-Ramírez, Alberto Jiménez-Moral |
| Novel drug resistance mechanisms and drug targets in BRAF-mutated peritoneal metastasis from colorectal cancer. Journal of translational medicine 2024 7 22 (1): 646. Christin Lund-Andersen, Annette Torgunrud, Chakravarthi Kanduri, Vegar J Dagenborg, Ida S Frøysnes, Mette M Larsen, Ben Davidson, Stein G Larsen, Kjersti Flatma |
| A novel necroptosis-related genes signature to predict prognosis and treatment response in bladder cancer. Frontiers in molecular biosciences 2024 12 11 1493411. Dongnuan Yao, Weitao Yu, Xueming Ma, Junqiang Ti |
- Page last reviewed:Feb 1, 2024
- Content source: